Cardiology/
Hematology
Diseases related to blood disorders, heart and the cardiovascular system
Pioneering Treatments in Cardiology and Hematology
Menagen is focused on delivering high-impact solutions for critical conditions in cardiology and hematology. Our research and development efforts aim to provide innovative therapies that improve patient outcomes and quality of life.
Our Areas of Focus in Cardiology and Hematology
Hematology
Addressing various blood disorders and malignancies.
What is Hematology?
Hematology is the study of blood in health and disease. It includes problems with the red blood cells, white blood cells, platelets, blood vessels, bone marrow, lymph nodes, spleen, and the proteins involved in bleeding and clotting (hemostasis and thrombosis). A hematologist is a medical doctor who applies this specialized knowledge to treat patients with blood conditions.
Solid Tumors
Providing targeted therapies for difficult-to-treat cancers.
solid tumors
A Solid Tumor is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors.
Heart Failure
Innovative treatments to support cardiac function and patient well-being.
Heart failure
Heart failure occurs when the heart muscle doesn't pump blood as well as it should. When this happens, blood often backs up and fluid can build up in the lungs, causing shortness of breath.
Some heart conditions slowly leave the heart too weak or stiff to fill and pump blood properly. These conditions include narrowed arteries in the heart and high blood pressure.
Proper treatment may improve the symptoms of heart failure and may help some people live longer. Lifestyle changes can improve quality of life. Try to lose weight, exercise, use less salt and manage stress.
But heart failure can be life-threatening. People with heart failure may have severe symptoms. Some may need a heart transplant or a device to help the heart pump blood.
Heart failure also may be called congestive heart failure.
Anemia of CKD & Chemotherapy
Managing anemia in patients with chronic kidney disease and those undergoing chemotherapy.
Anemia Management in Cancer Patients With CKD
Anemia is a common medical problem among patients with cancer and chronic kidney disease (CKD). Although anemia in patients with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients
Hyperphosphatemia in CKD
Treating elevated phosphate levels in chronic kidney disease.
Hyperphosphatemia Management in Patients with Chronic Kidney Disease
Hyperphosphatemia in chronic kidney disease (CKD) patients is a potentially life altering condition that can lead to cardiovascular calcification, metabolic bone disease (renal osteodystrophy) and the development of secondary hyperparathyroidism (SHPT). It is also associated with increased prevalence of cardiovascular diseases and mortality rates. To effectively manage hyperphosphatemia in CKD patients it is important to not only consider pharmacological and nonpharmacological treatment options but also to understand the underlying physiologic pathways involved in phosphorus homoeostasis.
Our Current Brands:
Menaxaparin®
Nitisinone 2 mg Capsules
Therapy for Hereditary Tyrosinemia Type I.
Darbegen®
Darbepoetin alfa 20/30/40/60 µg PFS
Supporting anemia management
Ryzeuta®
Efbemalenograstim alfa 20 mg / mL PFS
A key therapy in chemotherapy-induced neutropenia
Join Us in Transforming Healthcare
Explore our innovative solutions and become part of a healthier future for patients around the world.